Work

Pos1550 Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 (tyk2) Inhibitor, Deucravacitinib, on Psoriasis in Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial

Year: 2023

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2023-eular.1683

Authors: A.B. Gottlieb, A. Armstrong, J.F. Merola, A. Napoli, M. Nowak, S. Banerjee, T. Lehman, P.J. Mease

Institutions: Icahn School of Medicine at Mount Sinai, University of Southern California, Brigham and Women's Hospital, Harvard University, Bristol-Myers Squibb (United States), University of Washington, Swedish Medical Center

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Pfizer, XBiotech, Sun Pharma

OpenAlex ID: W4379796895

Cites:

Cited by:

Related to: 10